Verona (VRNA) Talks Up The Long View Following Phase II Setback
Verona Pharma (NASDAQ:VRNA) highlighted a surprising benefit from a lower [...]
By Bill Langbein|2019-03-07T14:59:36-05:00January 16th, 2019|Categories: Bill Langbein, Healthcare, Pharmaceutical & Biotechnology, SanaCurrents|Tags: Bill Langbein, RPL554, Verona, VRNA|
Verona Pharma (NASDAQ:VRNA) highlighted a surprising benefit from a lower [...]